Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
Hodi, F. Stephen , Hwu, Wen-Jen , Kefford, Richard , Weber, Jeffrey S. , Daud, Adil , Hamid, Omid , Patnaik, Amita , Ribas, Antoni , Robert, Caroline , Gangadhar, Tara C., Joshua, Anthony M. , Hersey, Peter , Dronca, Roxana , Joseph, Richard W. , Hille, Darcy A., Xue, Dahai, Li, Xiaoyun , Kang, Sunyu , Ebbinghaus, Scot, Perrone, Andrea , Joseph, Richard, Hille, Darcy, Li, Xiaoyun Nicole, Kang, S Peter, Wolchok, Jedd D, Hwu, Wen‐Jen , Wolchok, Jedd D. , Daud, Adil I , Weber, Jeffrey

Journal of Clinical Oncology | March 8, 2016 | Volume: 34 | Issue: 13 | Pages: 1510-1517

10.1200/jco.2015.64.0391 | PMID 26951310 Get It

Purpose We evaluated atypical response patterns and the relationship between overall survival and best overall response measured per immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) in patients with advanced melanoma treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827). Patients and Methods Patients received pembrolizumab 2 or 10 mg/kg every 2 weeks or every 3 weeks. Atypical responses were identified by using centrally assessed irRC data in patients with ≥ 28 weeks of imaging. Pseudoprogression was defined as ≥ 25% increase in tumor burden at week 12 (early) or any assessment after week 12 (delayed) that was not confirmed as progressive disease at next assessment. Response was assessed centrally per irRC and RECIST v1.1. Results Of the 655 patients with melanoma enrolled, 327 had ≥ 28 weeks of imaging follow-up. Twenty-four (7%) of these 327 patients had atypical responses (15 [5%] with early pseudoprogression and nine [3%] with delayed pseudoprogression). Of the 592 patients who survived ≥ 12 weeks, 84 (14%) experienced progressive disease per RECIST v1.1 but nonprogressive disease per irRC. Two-year overall survival rates were 77.6% in patients with nonprogressive disease per both criteria (n = 331), 37.5% in patients with progressive disease per RECIST v1.1 but nonprogressive disease per irRC (n = 84), and 17.3% in patients with progressive disease per both criteria (n = 177). Conclusion Atypical responses were observed in patients with melanoma treated with pembrolizumab. Based on survival analysis, conventional RECIST might underestimate the benefit of pembrolizumab in approximately 15% of patients; modified criteria that permit treatment beyond initial progression per RECIST v1.1 might prevent premature cessation of treatment.
Optimizing Mass Spectrometry Analyses: A Tailored Review on the Utility of Design of Experiments
Hecht, Elizabeth S. , Oberg, Ann L. , Muddiman, David C.

Journal of the American Society for Mass Spectrometry | March 7, 2016 | Volume: 27 | Issue: 5 | Pages: 767-785

10.1007/s13361-016-1344-x | PMID 26951559 Get It

Sudden Cardiac Death in the Young
Ackerman, Michael J. , Atkins, Dianne L. , Triedman, John K.

Circulation | March 7, 2016 | Volume: 133 | Issue: 10 | Pages: 1006-1026

10.1161/circulationaha.115.020254 | PMID 26951821 Get It

Although the occurrence of sudden cardiac death (SCD) in a young person is a rare event, it is traumatic and often widely publicized. In recent years, SCD in this population has been increasingly seen as a public health and safety issue. This review presents current knowledge relevant to the epidemiology of SCD and to strategies for prevention, resuscitation, and identification of those at greatest risk. Areas of active research and controversy include the development of best practices in screening, risk stratification approaches and postmortem evaluation, and identification of modifiable barriers to providing better outcomes after resuscitation of young SCD patients. Institution of a national registry of SCD in the young will provide data that will help to answer these questions.
Quantifying Intraoperative Workloads Across the Surgical Team Roles: Room for Better Balance?
Yu, Denny , Lowndes, Bethany R. , Thiels, Cornelius A. , Bingener, Juliane , Abdelrahman, Amro M. , Lyons, Rebecca , Lowndes, Bethany, Abdelrahman, Amro , Hallbeck, Susan, Hallbeck, M. Susan , Thiels, Cornelius A , Abdelrahman, Amro M

World Journal of Surgery | March 7, 2016 | Volume: 40 | Issue: 7 | Pages: 1565-1574

10.1007/s00268-016-3449-6 | PMID 26952115 Get It

Abstract Background Surgical performance, provider health, and patient safety can be compromised when workload demands exceed individual capability on the surgical team. The purpose of this study is to quantify and compare intraoperative workload among surgical team members. Methods Observations were conducted for an entire surgical day for 33 participating surgeons and their surgical team at one medical institution. Workload (mental, physical, case complexity, distractions, and case difficulty) was measured for each surgical team member using questions from validated questionnaires. Statistical analyses were performed with a mixed effects model. Results A total of 192 surgical team members participated in 78 operative cases, and 344 questionnaires were collected. Procedures with high surgeon mental and physical workload included endovascular and gastric surgeries, respectively. Ratings did not differ significantly among surgeons and residents, but scrub nurses physical demand ratings were 14–22 (out of 100) points lower than the surgeons, residents, and surgical assistants. Residents reported the highest mental workload, averaging 19–24 points higher than surgical assistants, scrub nurses, and circulating nurses. Mental and physical demands exceeded 50 points 28–45 % of the time for surgeons and residents. Workload did not differ between minimally invasive and open techniques. Conclusion The workload questionnaires are an effective tool for quantifying intraoperative workload across the surgical team to ensure mental and physical demands do not exceed thresholds where performance may decrease and injury risk increase. This tool has the potential to measure the safety of current procedures and drive design of workload interventions.
Robotics in otolaryngology and head and neck surgery: Recommendations for training and credentialing: A report of the 2015 AHNS education committee, AAO‐HNS robotic task force and AAO‐HNS sleep disorders committee
Magnuson, J. Scott , Duvvuri, Umamaheswar , Ghanem, Tamer , Yaremchuk, Kathleen , Goldenberg, David , Moore, Eric J. , Netterville, James L. , Weinstein, Gregory S., Richmon, Jeremy D. , Gross, Neil D , Holsinger, F. Christopher , Genden, Eric Michael , Miller, Matthew C. , Morris, Luc G T , Richmon, Jeremy D

Head & Neck | March 7, 2016 | Volume: 38 | Issue: S1 | Pages: No page available

10.1002/hed.24207 | PMID 26950771 Get It

AbstractTraining and credentialing for robotic surgery in otolaryngology ‐ head and neck surgery is currently not standardized, but rather relies heavily on industry guidance. This manuscript represents a comprehensive review of this increasingly important topic and outlines clear recommendations to better standardize the practice. The recommendations provided can be used as a reference by individuals and institutions alike, and are expected to evolve over time. © 2016 Wiley Periodicals, Inc. Head Neck 38: E151–E158,
Melatonin Pathway and Atenolol‐Related Glucose Dysregulation: Is There a Correlation?
McDonough, Caitrin W. , LANGAEE, T, Kenari, N Nasiri, Beitelshees, AL, Gums, John G. , Chapman, AB, Turner, ST, Johnson, JA, Cooper‐DeHoff, RM, Johnson, Julie A. , Beitelshees, Amber L. , Beitelshees, Amber L. , Chang, SW, Gong, Yan , Cooper-DeHoff, RM

Clinical and Translational Science | March 7, 2016 | Volume: 9 | Issue: 2 | Pages: 114-122

10.1111/cts.12389 | PMID 26946962 Get It

Lower melatonin level, melatonin receptor gene variations, and atenolol treatment are associated with glucose dysregulation. We investigated whether atenolol‐related glucose and melatonin changes are correlated, and whether single nucleotide polymorphisms (SNPs) in melatonin candidate genes contribute to interindividual variation in glucose change. Hypertensive Caucasians (n = 232) from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study treated with atenolol for 9 weeks were studied. Urinary 6‐sulfatoxymelatonin (aMT6s) was measured pre‐ and posttreatment and normalized to urinary creatinine. Pharmacogenetic effects on glucose change of 160 SNPs in 16 melatonin candidate genes were assessed with multiple linear regression. Atenolol was associated with increased glucose (1.8 ± 10.1mg/dl, P = 0.02) and decreased aMT6s (–4.5 ± 10.1 ng/mg, P < 0.0001). However, the aMT6s change was not correlated with post‐atenolol glucose change. SNP rs11649514 in PRKCB was associated with glucose change (P = 1.0×10−4). PRKCB is involved in the melatonin‐insulin regulatory pathway, and may be important in mediating clinically meaningful atenolol‐related hyperglycemia.
Genetic effects on sleep/wake variation of seizures
Winawer, Melodie R., Shih, Jerry J. , Hunter, Jessica Ezzell , Epstein, Michael P. , Investigators, the EPGP, Sadleir, Lynette G. , Shih, Jerry, Beck, Erin S , Investigators, the EPGP

Epilepsia | March 7, 2016 | Volume: 57 | Issue: 4 | Pages: 557-565

10.1111/epi.13330 | PMID 26948972 Get It

SummaryObjectiveThere is a complex bidirectional relationship between sleep and epilepsy. Sleep/wake timing of seizures has been investigated for several individual seizure types and syndromes, but few large‐scale studies of the timing of seizures exist in people with varied epilepsy types. In addition, the genetic contributions to seizure timing have not been well studied.MethodsSleep/wake timing of seizures was determined for 1,395 subjects in 546 families enrolled in the Epilepsy Phenome/Genome Project (EPGP). We examined seizure timing among subjects with different epilepsy types, seizure types, epilepsy syndromes, and localization. We also examined the familial aggregation of sleep/wake occurrence of seizures.ResultsSeizures in nonacquired focal epilepsy (NAFE) were more likely to occur during sleep than seizures in generalized epilepsy (GE), for both convulsive (odds ratio [OR] 5.2, 95% confidence interval [CI] 3.59–7.52) and nonconvulsive seizures (OR 4.2, 95% CI 2.48–7.21). Seizures occurring within 1 h of awakening were more likely to occur in patients with GE than with NAFE for both convulsive (OR 2.3, 95% CI 1.54–3.39) and nonconvulsive (OR 1.7, 95% CI 1.04–2.66) seizures. Frontal onset seizures were more likely than temporal onset seizures to occur during sleep. Sleep/wake timing of seizures in first‐degree relatives predicted timing of seizures in the proband.SignificanceWe found that sleep/wake timing of seizures is associated with both epilepsy syndrome and seizure type. In addition, we provide the first evidence for a genetic contribution to sleep/wake timing of seizures in a large group of individuals with common epilepsy syndromes.
Validating endpoints for therapeutic trials in fecal incontinence
Noelting, Jessica , Zinsmeister, Alan R., Bharucha, Adil E.

Neurogastroenterology & Motility | March 7, 2016 | Volume: 28 | Issue: 8 | Pages: 1148-1156

10.1111/nmo.12809 | PMID 26948292 Get It

AbstractBackgroundA 50% or greater reduction in the frequency of fecal incontinence (FI) recorded with daily bowel diaries is the primary endpoint in clinical trials of FI. Whether this difference is clinically important is unknown. The relationship between FI symptoms recorded with daily and weekly instruments is unknown. The contribution of psychological factors to quality of life (QOL) in FI is unclear.MethodsFecal incontinence severity was assessed with daily bowel diaries and periodic questionnaires (fecal incontinence severity score [FISS], FIQOL, 36‐Item Short Form Health Survey [SF‐36], and hospital anxiety and depression scales) for 4 weeks before and during double‐blind randomization to placebo or clonidine in 44 women with FI. The reduction in FI frequency was compared to the minimal clinically important difference (MCID) computed from the FISS. Endpoints of FI were compared between daily and weekly diaries.Key ResultsThe FISS exceeded the MCID in 75% and 83% of patients in whom the FI frequency declined by 50–74% and ≥75% respectively. Parameters of FI measured with daily and weekly instruments were significantly correlated. The daily parameters explained 71% of the inter‐patient variation in the FISS. The SF‐36 health scores, rather than the FISS rating, explained a majority of the inter‐subject variation in FIQOL.Conclusions & InferencesMost patients who report a ≥50% reduction in FI frequency experience a clinically important improvement. Weekly questionnaires accurately assess the severity of FI. Self‐reported physical and mental health explained a greater proportion of the variance in FIQOL than FI symptom severity.
Report of the ASFA apheresis registry on muscle specific kinase antibody positive myasthenia gravis
Yamada, Chisa , Pham, Huy P. , Wu, Yanyun , Cooling, Laura , Kim, Haewon C., Morgan, Shanna, Wong, Edward C.C. , Winters, Jeffrey L. , Schwartz, Joseph E. , Pham, Huy P , Yamada, Chisa

Journal of Clinical Apheresis | March 6, 2016 | Volume: 32 | Issue: 1 | Pages: 5-11

10.1002/jca.21454 | PMID 26946363 Get It

Background: Anti‐muscle specific kinase antibody positive (MuSK Ab) myasthenia gravis (MG) patients are known to have different clinical course compared to anti‐acetylcholine receptor Ab positive MG patients. Therapeutic plasma exchange (TPE) has been reported to be effective; however, little is known of the response and of TPE procedural information. An ASFA Apheresis Registry was developed to analyze those data. Methods: The study collected detailed de‐identified patient data, TPE procedures, and treatment outcome/complications. Collected data was described in aggregate. Results: A total of 15 MuSK Ab MG patients with exacerbation of MG symptoms, 13 females/2 males, median age 44, were investigated. Thirty TPE courses (median 5 procedures/course, total 145 procedures) were evaluated. All TPE procedures were performed with citrate anticoagulation, 1 − 1.25 plasma volume exchange in 100% fluid balance, and 90% of courses used only albumin as replacement. Calcium was added to albumin or given orally as needed. TPE was performed every other day in 55% of courses. Adverse events occurred in 3.4% of procedures. Ten patients (67%) experienced relapses within a median of 7 weeks. Objective symptoms were resolved in more than 75% of courses. Overall subjective improvement rates were 94.1%/93.3% after 3/4 TPE procedures, respectively. Thirty‐one percent of patients responded poorly with minimal recovery. Conclusion: Overall subjective improvement was seen up to 94% of patients after one course of TPE. Some patients were poor‐responders. Five TPE may be adequate for initial course with additional TPE as needed. Based upon this preliminary data, we will modify our future data collection. J. Clin. Apheresis 32:5–11, 2017. © 2016 Wiley Periodicals, Inc.